Drug intelligence / Profile preview

PRT-001 (Protai)

Development stage: Preclinical
Lead developer: Protai
Modality: Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

PRT-001 is a targeted protein degrader (TPD) being developed by Protai for the treatment of oncology indications, including breast cancer and other solid tumors. It specifically targets KAT6A (Lysine acetyltransferase 6A), an epigenetic regulator often dysregulated in various cancers. Developed using Protai's AI-driven AIMS™ platform, which integrates structural proteomics and mass spectrometry, PRT-001 aims to eliminate KAT6A protein activity rather than just inhibiting it. The program is currently in the IND-enabling stage, with an IND filing anticipated in 2027.

Other names: KAT6A degraderKAT-6A degraderKAT 6A degrader

Targets

KAT6A (Lysine acetyltransferase 6A)

Beyond the preview

Go deeper on PRT-001 (Protai).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRT-001 (Protai).

Explore the full profile